GGrantIndex
← Leaderboards

Al B Benson

Northwestern University

$11,593,650
Attributed
$17,678,242
Total exposure
11
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,206,015 · 10
FDA$4,472,227 · 1

By mechanism

U10$6,063,420 · 1
UG1$5,460,843 · 1
U01$4,472,227 · 1
P30$1,665,812 · 4
M01$15,940 · 4

Top collaborators

Most similar at Northwestern University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchClinical TrialsComprehensive Cancer CenterMalignant NeoplasmsMemberCancer CenterProgramsEnsureUniversitiesResourcesGrantEastern Cooperative Oncology GroupAncillary StudyScienceDisciplinePathologyInstitutionLeadershipTranslational ResearchResearch PersonnelLaboratoriesPublicationsCollaborationsCancer Patient

Grant awards (49)

Northwestern University Lead Academic Participating Site$463,643
UG1 · FY2025 · CA · contact PI
Protocol Review and Monitoring System$121,423
P30 · FY2025 · CA · contact PI
Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making$2,247,715
U01 · FY2024 · FD
Northwestern University Lead Academic Participating Site$949,402
UG1 · FY2024 · CA · contact PI
Protocol Review and Monitoring System$171,974
P30 · FY2024 · CA · contact PI
Northwestern University Lead Academic Participating Site - Revision -5S2$42,000
UG1 · FY2024 · CA · contact PI
Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making$2,224,512
U01 · FY2023 · FD
Northwestern University Lead Academic Participating Site$775,160
UG1 · FY2023 · CA · contact PI
Northwestern University Lead Academic Participating Site, GY4 Supplemental Request$299,998
UG1 · FY2023 · CA · contact PI
Protocol Review and Monitoring System$171,974
P30 · FY2023 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2022 · CA · contact PI
Protocol Review and Monitoring System$234,357
P30 · FY2022 · CA · contact PI
Northwestern University Lead Academic Participating Site$895,160
UG1 · FY2021 · CA · contact PI
Northwestern University Lead Academic Participating Site Supplement Year 2$315,000
UG1 · FY2021 · CA · contact PI
Protocol Review and Monitoring System$234,357
P30 · FY2021 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$234,357
P30 · FY2020 · CA · contact PI
Northwestern University Lead Academic Participating Site$175,000
UG1 · FY2020 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$234,357
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$239,009
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$8,620
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$8,488
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$6,896
P30 · FY2018 · CA · contact PI
ECOG Clinical Trials$362,638
U10 · FY2013 · CA · contact PI
ECOG Clinical Trials$415,756
U10 · FY2012 · CA · contact PI
ECOG Clinical Trials$415,756
U10 · FY2011 · CA · contact PI
ECOG Clinical Trials$455,484
U10 · FY2010 · CA · contact PI
Eastern Cooperative Oncology Group Clinical Trials$460,085
U10 · FY2009 · CA · contact PI
Eastern Cooperative Oncology Group Clinical Trials$452,395
U10 · FY2008 · CA · contact PI
Eastern Cooperative Oncology Group Clinical Trials$456,370
U10 · FY2007 · CA · contact PI
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS$5,940
M01 · FY2007 · RR · contact PI
Eastern Cooperative Oncology Group Clinical Trials$448,417
U10 · FY2006 · CA · contact PI
Eastern Cooperative Oncology Group Clinical Trials$446,382
U10 · FY2005 · CA
NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS$4,144
M01 · FY2005 · RR
Eastern Cooperative Oncology Group Clinical Trials$459,386
U10 · FY2004 · CA
NU 98X3: Irinotecan (CPT-11) and Gemcitabine in Patients with Solid Tumors$5,856
M01 · FY2004 · RR
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS$434,415
U10 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS$434,415
U10 · FY2002 · CA
CORE--CLINICAL RESEARCH OFFICE$0
P30 · FY2002 · CA
CORE--CLINICAL RESEARCH OFFICE$0
P30 · FY2002 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS$417,036
U10 · FY2001 · CA
PHASE I TRIAL OF IRINOTECAN (CPT 11) AND GEMCITABINE$0
M01 · FY2001 · RR
CORE--CLINICAL TRIAL PROTOCOL REVIEW/MONITORING SYSTEM$0
P30 · FY2001 · CA
CORE--CLINICAL RESEARCH OFFICE$0
P30 · FY2001 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP CLINICAL TRIALS$404,885
U10 · FY2000 · CA
CORE--CLINICAL RESEARCH OFFICE$0
P30 · FY2000 · CA
CORE--CLINICAL RESEARCH OFFICE$0
P30 · FY2000 · CA
PHASE I TRIAL OF IRINOTECAN (CPT 11) AND GEMCITABINE$0
M01 · FY2000 · RR